Thornburg Investment Management Inc. Invests $13.34 Million in IQVIA Holdings Inc. $IQV

Thornburg Investment Management Inc. bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 69,029 shares of the medical research company’s stock, valued at approximately $13,338,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of IQVIA by 9.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after purchasing an additional 134,997 shares during the period. Royal London Asset Management Ltd. raised its holdings in IQVIA by 1.0% during the 2nd quarter. Royal London Asset Management Ltd. now owns 79,234 shares of the medical research company’s stock valued at $15,310,000 after buying an additional 756 shares during the last quarter. Mufg Securities Americas Inc. raised its holdings in IQVIA by 7.1% during the 2nd quarter. Mufg Securities Americas Inc. now owns 5,027 shares of the medical research company’s stock valued at $971,000 after buying an additional 334 shares during the last quarter. Van ECK Associates Corp boosted its position in IQVIA by 1.9% during the 2nd quarter. Van ECK Associates Corp now owns 117,970 shares of the medical research company’s stock valued at $22,794,000 after buying an additional 2,171 shares during the period. Finally, Nissay Asset Management Corp Japan grew its holdings in IQVIA by 3.8% in the 2nd quarter. Nissay Asset Management Corp Japan now owns 22,745 shares of the medical research company’s stock worth $4,395,000 after acquiring an additional 839 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on IQV. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Stifel Nicolaus increased their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $241.88.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 over the last three months. 1.70% of the stock is owned by corporate insiders.

IQVIA Price Performance

Shares of IQV opened at $260.48 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $265.25. The firm’s 50-day simple moving average is $222.14 and its two-hundred day simple moving average is $189.62. The stock has a market cap of $42.88 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.